Toby Trahair

Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial.

Günter Schreier, Ruth Ladenstein, Henrik Schroeder, 2017, The Lancet. Oncology.

Zero childhood cancer – Accelerating translation of experimental oncology: Better matching drug to target

Mark Pinese, Mark J. Cowley, Jinhan Xie, 2018 .

Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial.

Ruth Ladenstein, Henrik Schroeder, Ulrike Pötschger, 2018, The Lancet. Oncology.